Biotech

All Articles

Analysts go into Avidity's DMD gain, uncovering distinctions in information

.Avidity Biosciences impressed real estate investors along with period 1/2 data in Duchenne muscle d...

Actinogen's cortisol blocker fails period 2 anxiety research study

.Actinogen Medical's cortisol blocker has missed out on the major endpoint of a period 2 research in...

Bivictrix makes a decision going personal only technique to take ADC into center

.Antibody-drug conjugates (ADCs) have actually been at the center of numerous a billion-dollar biobu...

TPG leadings up funds to $580M for assets around lifestyle sciences

.Asset manager TPG, which has assisted biotechs like Sionna Therapies as well as Santa Clam Ana Biog...

Merck ceases stage 3 TIGIT trial in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT program has endured one more trouble. Months after shuttering a phase 3 mela...

After a difficult year, Exscientia folds right into Recursion

.After a year determined by pipe cuts, the departure of its CEO and layoffs, Exscientia will definit...

Cullinan, after $25M package, return bispecific to Port

.Cullinan Therapeutics was wowed sufficient along with Port BioMed's bispecific invulnerable reactor...

A closer check out Brutal Biotech's Intense 15

.In this particular full week's incident of "The Best Pipe," our team are actually diving into Fierc...

Lilly encounters period 2 breakdown of tau-targeting med

.The confetti is still flying from Eli Lilly's celebration celebrating the approval of Alzheimer's i...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of substantial management hirings, shootings and...